Clinical trials: Early-Stage Breast Carcinoma
Early-stage Breast Cancer, Invasive Ductal Carcinoma of Female Breast
Radiation After No Axillary Nodal Sampling
This is a single arm, pilot, prospective study to evaluate the safety of partial breast irradiation in women who undergo breast conserving surgery without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection…
- Trial name
- RADIANS (NCT07723209)
- Testing
- Partial Breast Irradiation (PBI)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- NYU Langone Health
Omitting Sentinel Lymph Node Biopsy in Early-stage Breast Cancer
De-escalation in Axillary Surgery for Early-stage Breast Cancer
The goal of this clinical trial is to determine if the omission of sentinel lymph node biopsy is safe for early-stage breast cancer patients in our institution (Clinical Hospital Centre Rijeka).
- Trial name
- RIDES (NCT07098507)
- Testing
- sentinel lymph node biopsy, omission of sentinel lymph node biopsy
- Where
- Croatia
- Volunteers
- 620 people
- Sponsor
- Clinical Hospital Center Rijeka
Breast Cancer Female
Radiofrequency Ablation (RFA) in Breast Tumors
To validate the efficacy and safety of the cool-tip ablation method for breast tumors smaller than 2 cm.
- Trial name
- RFA (NCT04389216)
- Testing
- Cool-tip electrode for Radiofrequency Ablation
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitari de Bellvitge
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement.
- Conditions
- Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
- Trial name
- PROFFi (NCT06113016)
- Testing
- Biospecimen Collection, Educational Intervention, Exercise Intervention
- Where
- 6 sites in United States
- Volunteers
- 164 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Early and Locally Advanced Breast Cancer
ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
The goal of this performance study is to learn if treatment with neoadjuvant endocrine therapy compared to chemotherapy has comparable efficacy, but better quality of life outcomes in endocrine responsive participants with early…
- Trial name
- TEODOR (NCT07084558)
- Testing
- blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived)
- Where
- 14 sites in Austria
- Volunteers
- 350 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer
A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early
Patients with localized primary breast cancer including inflammatory breast cancer suitable for primary medical treatment and/or regional lymph node metastases receive six cycles of chemotherapy with epirubicin and docetaxel.
- Trial name
- PROMIX (NCT00957125)
- Testing
- Epirubicin, Docetaxel, Bevacizumab
- Where
- 6 sites in Sweden
- Volunteers
- 151 people
- Sponsor
- Thomas Hatschek
Breast Cancer, HER2 + Breast Cancer
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
The aim of this study is to evaluate the efficacy and safety of TQB2102 compared to TCbHP in the neoadjuvant treatment of HER2-positive breast cancer.
- Trial name
- NCT07136974
- Testing
- TQB2102, Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
This is a prospective, registry trial which will enroll women aged 65 and above with early stage, low risk breast cancer who will be treated with partial mastectomy and intraoperative radiation therapy (IORT).
- Trial name
- NCT03536897
- Testing
- IORT
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Mount Carmel Health System
Breast Cancer
PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Non-randomized, open label, multicentric translational research study in women with untreated invasive breast carcinoma eligible for primary surgery (Stage I-IIIA).
- Trial name
- PAMELA (NCT01973660)
- Testing
- Lapatinib, Trastuzumab, Endocrine Therapy
- Where
- 22 sites in Spain
- Volunteers
- 151 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2…
- Trial name
- NCT07054190
- Testing
- Inavolisib, Ribociclib, Letrozole
- Where
- 37 sites in United States, Argentina and 5 more
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
Sarcopenia, Paclitaxel Induced Neuropathy
Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)
This prospective observational study aims to investigate the relationship between sarcopenia and the development of paclitaxel-induced peripheral neuropathy in patients with early-stage breast cancer.
- Conditions
- Sarcopenia, Paclitaxel Induced Neuropathy, Breast Carcinoma
- Trial name
- Neuro-Sarc (NCT06996548)
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Gazi University
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
Current guidelines as those from the AGO-Breast commission recommend for neoadjuvant breast cancer patients either a sequence of 4 cycles EC followed by 4 cycles of a taxane or 6 cycles of TAC based on previous large scale…
- Conditions
- Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer
- Trial name
- GeparSepto (NCT01583426)
- Testing
- nab-Paclitaxel, Paclitaxel
- Where
- Germany
- Volunteers
- 1,229 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor…
- Trial name
- NCT05967884
- Testing
- Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
This study is a multicenter, prospective, randomized phase II trial designed to observe and evaluate the efficacy and safety of trastuzumab, pertuzumab, docetaxel combined with QL1706 versus combined with carboplatin as…
- Trial name
- NCT07246317
- Testing
- QL1706 injection, Trastuzumab (or biosimilar), Pertuzumab (or biosimilar)
- Where
- 8 sites in China
- Volunteers
- 188 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer
RATIONALE: Diagnostic procedures that detect tumor cells in the bone marrow may help doctors predict disease recurrence and plan more effective treatment.
- Trial name
- NCT00089323
- Testing
- Bone Marrow Aspiration
- Where
- 53 sites in United States, Canada
- Volunteers
- 1,630 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer, Early Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who…
- Trial name
- CAMBRIA-1 (NCT05774951)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 709 sites in United States, Argentina and 37 more
- Volunteers
- 4,300 people
- Sponsor
- AstraZeneca
Breast Cancer
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Anthracycline-containing regimens are recommended as adjuvant treatment for women with node positive breast cancer. In at least three large randomized clinical trials the addition or sequential administration of a taxane…
- Trial name
- NCT00431080
- Testing
- Docetaxel, Paclitaxel, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 478 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology
This study will evaluate LumaScan, an innovative polarization microscope for real time, intraoperative imaging and evaluation of the surface of excised tissue excised during Breast Conservation Surgery (BCS) for non invasive and…
- Trial name
- NCT02207179
- Testing
- LumaScan Image Guided Surgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- LumaMed
Breast Cancer
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive…
- Trial name
- LISAH (NCT01928615)
- Testing
- Trastuzumab - intravenous solution, Trastuzumab - subcutaneous solution, Chemotherapy
- Where
- 2 sites in Austria
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TACT2 (NCT00301925)
- Testing
- pegfilgrastim, capecitabine, cyclophosphamide
- Where
- 152 sites in United Kingdom
- Volunteers
- 4,400 people
- Sponsor
- Institute of Cancer Research, United Kingdom